These results are consistent with cancer-associated mutations in PKCθ being loss-of-function, as shown previously for other PKC isozymes, and support a model in which cancer therapeutic strategies should focus on restoring PKCθ activity rather than inhibiting it. This evidence concerns the gene PRRT2 and cancer.